论文部分内容阅读
目的:观察多西他赛联合卡培他滨二线治疗转移性乳腺癌的疗效及其安全性。方法:对26例一线治疗后进展的转移性乳腺癌患者,予多西他赛注射液35mg/㎡+生理盐水250mL静脉滴注,第1天和第8天给予;卡培他滨1000mg/㎡,口服,每天2次,第1~14天给予。每21d为1个周期,至少应用2个周期。结果:完全缓解4例,部分缓解13例,稳定5例,进展4例。总有效率为65%,临床获益率为85%。常见的血液、胃肠道和神经系统的不良反应可以耐受。结论:采用多西他赛联合卡培他滨治疗转移性乳腺癌,其临床疗效能进一步提高,不良反应并无增加,可作为治疗转移性乳腺癌二线方案优先选用。
Objective: To observe the efficacy and safety of docetaxel combined with capecitabine in the treatment of metastatic breast cancer. Methods: Twenty-six patients with metastatic breast cancer who progressed after the first-line therapy were given intravenous drip of docetaxel 35 mg / m 2 and 250 mL normal saline on days 1 and 8. Capecitabine 1000 mg / m 2 , Orally, 2 times a day, the first to 14 days to give. Every 21d for a period of at least two cycles. Results: Complete remission in 4 cases, partial remission in 13 cases, stable in 5 cases, progress in 4 cases. The total effective rate was 65%, the clinical benefit rate was 85%. Common blood, gastrointestinal and nervous system adverse reactions can be tolerated. Conclusion: Docetaxel combined with capecitabine in the treatment of metastatic breast cancer, the clinical efficacy can be further improved without any increase in adverse reactions, can be used as a priority for the treatment of metastatic breast cancer second-line program.